Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Keywords

Homepage

Brief description/objective

Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase IIb study to evaluate the efficacy, safety, and tolerability of three doses of an oral S1P1 receptor agonist, administered for twenty-four weks in patients with relapsing-remitting multiple sclerosis

Primary Outcome meassures:
culmulative number of new gadolinium lesions T1-weighted MRI at weeks 12/16/20/24

Secondary objectives:
- annualized confirmed relapse rate
- time to first confirmed relapse
- safety and tolarability